Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-10-22

FDA Approved: VYEPTI — Supplemental Application (Lundbeck Pharmaceuticals LLC)

View source ↗

Summary

FDA approved a supplemental application for VYEPTI (epinezumab-jjmr) submitted by Lundbeck Pharmaceuticals LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VYEPTI (eptinezumab)

Snippet

SUPPL AP for VYEPTI (EPTINEZUMAB-JJMR)